Nouvelle déclaration d'incident
No de la demande: 2014-2950
Numéro de référence du titulaire d'homologation: 1396684
Nom du titulaire (nom légal complet, aucune abbréviation): Bell Laboratories, Inc.
Adresse: 3699 Kinsman Blvd
Ville: Madison
État: WI
Pays: USA
Code postal /Zip: 53704
Incident chez l'humain
Pays: UNITED STATES
État: NEW YORK
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 12455-120-3240
Nom du produit: Tomcat Mouse Killer I (refillable resistant bait station)
Appât
Oui
Inconnu
Site: Res. - In Home / Rés. - à l'int. maison
Personne affectée
Sexe: Homme
Âge: >19 <=64 yrs / >19 <=64 ans
Système
Unknown / Inconnu
Oui
Oui
9
Day(s) / Jour(s)
Non professionnel
Application
Quelle était l'activité? Please refer to field 13 on Subform II or field 17 of subform III for a detailed description regarding the activity
Autre
Aucun
Peau
Orale
<=15 min / <=15 min
Unknown / Inconnu
June 4, 2014. Caller has a prior medical history consisting of hypertension and Hepatitis C prior to his alleged exposure on May 10, 2014. Caller alleges that on May 10, 2014 while he was opening a bag of the product, the air from inside of the bag was emitted and reached his face. He indicated that after this exposure to the air, he experienced what he thought was a chemical taste. He was not exposed to the actual wax block of rodenticide. Two days following this exposure, he developed facial, lip, eye and neck swelling. Caller states that sometimes his whole body swells and his abdomen becomes very hard. This may likely have something to do with his Hepatitis C. Caller also states that he has fevers at night and that he is very forgetful. Caller states that he spent 1 week in the hospital but forgot to tell his doctor of his recent use of the rodenticide. Caller states that he is still swollen. Caller states that 3 days after the original exposure, he went to an allergy specialist because he was still having the swelling and a numbness and he was given an epi-pen and antihistamine. Caller never used the epi-pen but was using the antihistamine. Caller also added in that his eyes were constantly burning and were red, so his allergy MD gave him ketotifen fumarate. Caller then started to sovaldi and ribavirin for his Hepatitis C and then he lost his voice. Caller cannot recall when he was originally diagnosed with Hepatitis C but it had been several months ago. Caller then went to the ER and they kept him in the hospital for 6-7 days, but he cannot remember why but he thinks it was because he lost his voice. Caller added that inside his head was numb and also one side of his face was numb. They ran MRIs and cat scans which came back normal. Caller's hepatologist came to the hospital and took him off of the solvaldi after 4 days of being on it. Caller states that he was discharged home with a diagnosis of a "speech problem" and his vocal cord on the left of his neck was lazy. Caller denies any diagnosis of a stroke. Follow-up on June 9, 2014. Caller went to ER, and had another MRI, this time with contrast. No problems were found. No treatments were rendered. He was admitted again for 2 days, and had CAT scan, which also showed no problems. He still has abdominal swelling, but this has improved somewhat. He continues to experience problems from his hepatitis.
Majeure
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews. Any relationship between the use of this product and the insidious development of the complications reported in this case is inconceivable and lacks biological plausibility. Secondly, the product use history is extremely vague and lacks any description of a known or defined point of direct exposure to physical wax rodenticide. Even had casual or incidental contact with this product occurred, such illness would be unexpected and is not consistent with the toxicological profile of this product. This patient's complications appear to be an extension of a serious Hepatitis C infection.